Open AccessNitric oxide — soluble guanylate cyclase — cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets
Author(s) -
Ж. Д. Кобалава,
П. В. Лазарев
Publication year - 2021
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2021-3035
Subject(s) - cyclic guanosine monophosphate , guanylate cyclase , medicine , gucy1a3 , nitric oxide , guanosine , gucy1b3 , heart failure , pathogenesis , guanylate cyclase 2c , pharmacology , guanosine monophosphate , signal transduction , stimulation , biochemistry , biology , nucleotide , gene
Heart failure is a severe disease with an unfavorable prognosis, which requires intensification of therapy and the search for novel approaches to treatment. In this review, the physiological significance of soluble guanylate cyclase-related signaling pathway, reasons for decrease in its activity in heart failure and possible consequences are discussed. Pharmacological methods of stimulating the production of cyclic guanosine monophosphate using drugs with different mechanisms of action are considered. Data from clinical studies regarding their effectiveness and safety are presented. A promising approach is stimulation of soluble guanylate cyclase, which showed beneficial effects in preclinical studies, as well as in the recently completed phase III VICTORIA study.